Aclaris Therapeutics (ACRS) Insider Trading & Ownership → The new financial threat that could wipe out millions… (From InvestorPlace) (Ad) Free ACRS Stock Alerts $1.22 -0.12 (-8.96%) (As of 05/8/2024 ET) Add Compare Share Share Insider TradesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Aclaris Therapeutics (NASDAQ:ACRS) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage5.50%Number OfInsiders Buying(Last 12 Months)1Amount OfInsider Buying(Last 12 Months)$99,994.00Number OfInsiders Selling(Last 12 Months)1Amount OfInsider Selling(Last 12 Months)$136,080.00 Get ACRS Insider Trade Alerts Want to know when executives and insiders are buying or selling Aclaris Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address ACRS Insider Buying and Selling by Quarter Ad Unstoppable Prosperity“Crash Insurance” For Your RetirementWhen it comes to retirement, everyone fears one thing… Outliving their retirement savings. You'll discover conservative, beginner-friendly options strategies which could help to cash flow your stock portfolio. Click here to register for free. Aclaris Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails10/23/2023Joseph MonahanInsiderSell6,000$5.08$30,480.00 8/28/2023James LoeropInsiderBuy14,705$6.80$99,994.00 8/21/2023Joseph MonahanInsiderSell6,000$7.32$43,920.00 6/20/2023Joseph MonahanInsiderSell6,000$10.28$61,680.00 (Data available from 1/1/2013 forward) ACRS Insider Trading Activity - Frequently Asked Questions Who is on Aclaris Therapeutics's Insider Roster? The list of insiders at Aclaris Therapeutics includes Andrew N Schiff, David N Gordon, Douglas J Manion, Frank Ruffo, James Loerop, Joseph Monahan, Kamil Ali-Jackson, Kevin Balthaser, and Neal Walker. Learn more on insiders at ACRS. What percentage of Aclaris Therapeutics stock is owned by insiders? 5.50% of Aclaris Therapeutics stock is owned by insiders. Learn more on ACRS's insider holdings. Which Aclaris Therapeutics insiders have been buying company stock? The following insiders have purchased ACRS shares in the last 24 months: Douglas J Manion ($50,310.00), and James Loerop ($99,994.00). How much insider buying is happening at Aclaris Therapeutics? Insiders have purchased a total of 21,205 ACRS shares in the last 24 months for a total of $150,304.00 bought. Which Aclaris Therapeutics insiders have been selling company stock? The following insiders have sold ACRS shares in the last 24 months: Andrew N Schiff ($1,565,033.42), James Loerop ($59,268.63), Joseph Monahan ($478,456.00), Kevin Balthaser ($12,290.00), and Neal Walker ($739,980.00). How much insider selling is happening at Aclaris Therapeutics? Insiders have sold a total of 216,271 Aclaris Therapeutics shares in the last 24 months for a total of $3,151,242.15 sold. More Insider Trading Tools from MarketBeat Related Companies: Reviva Pharmaceuticals Insider Buying Milestone Pharmaceuticals Insider Buying Hookipa Pharma Insider Buying Assertio Insider Buying vTv Therapeutics Insider Buying Chimerix Insider Buying Genelux Insider Buying ProPhase Labs Insider Buying Q32 Bio Insider Buying Eton Pharmaceuticals Insider Buying Insider Tracking Tools: CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country: U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles: 3 Penny Stocks That Insiders Are BuyingThe 3 Hottest Insiders Buys This Month 3 Companies Buying Back Cheap Stock LatelyPagaya Technologies: An AI Fintech That Insiders Are BuyingThe 5 Stocks Most Sold By Insiders This Year This page (NASDAQ:ACRS) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaAI “wealth window” is closing June 25thParadigm PressCharles Payne Demystifies OptionsUnstoppable ProsperityThe AI Stock that’s Disrupting Every IndustryStockEarningsShocking: One AI startup's revenue could surge 4,735%Manward Press[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aclaris Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.